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Abstract 18 
Introduction:  19 
The diagnosis of pleural tuberculosis (TB) is problematic. The comparative performance of 20 
newer same day tools for pleural TB including Xpert MTB/RIF Ultra (ULTRA) has, hitherto, 21 
not been comprehensively been studied.  22 
Methods:  23 
Adenosine deaminase (ADA), Inter-Gam Ultrasensitive Rapid Immuno-suspension Assay 24 
(IRISA-TB), Xpert MTB/RIF, and ULTRA performance outcomes were evaluated in pleural 25 
fluid samples from 149 patients with suspected pleural TB. The reference standard was 26 
culture positivity (fluid, biopsy or sputum) and/or pleural biopsy histopathology (definite-27 
TB). Those with non-TB were microbiologically test negative and were not initiated on anti-28 
TB treatment. To determine the effect of sample concentration, 65 samples underwent 29 
pelleting by centrifugation followed by conventional Xpert MTB/RIF and ULTRA.  30 
Results:  31 
Of the 149 patients, 49 had definite-TB, 16 probable-TB (not definite but treated for TB) and 32 
84 non-TB. ULTRA sensitivity (95% CI) and specificity was similar to Xpert MTB/RIF 33 
[37.5% (25.3-51.2) versus 28.6% (15.9-41.2)] and [98.8% (96.5-100) versus 98.8% (96.5-34 
100)], respectively. Centrifugation did not significantly improve ULTRA sensitivity (29.5% 35 
vs. 31.3%, respectively). Adenosine deaminase and IRISA-TB sensitivity was 84.4% (73.9 – 36 
95.0) and 89.8% (81.3– 98.3), respectively. However, IRISA-TB demonstrated significantly 37 
better specificity [96.4% vs. 87.5% (p= 0.034)], positive-predictive value [93.6% vs. 80.9 (p= 38 
0.028)] and positive-likelihood ratio [25.1 vs. 6.8 (p= 0.032)] than ADA. 39 
Conclusion:  40 
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Xpert ULTRA has poor sensitivity for the diagnosis of pleural TB.  Alternative assays (ADA 41 
and IRISA-TB) are significantly more sensitive, with IRISA-TB demonstrating a higher 42 
specificity and rule-in value compared to ADA in this high TB and HIV-endemic setting. 43 
 44 
Word Count: 240/250 45 
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Introduction 47 
Tuberculosis (TB) remains a global health problem with 10 million new cases attributable to 48 
the disease in 2017 (1). Although pulmonary TB is the predominant form of the disease, 49 
extra-pulmonary TB (EPTB) accounts for approximately 25% of active cases (2), with 50 
pleural TB being the a common manifestation of EPTB (3), if not the most common in 51 
several settings (4-6). The diagnosis of pleural TB is difficult due to the paucibacillary nature 52 
of the disease and the need for invasive sampling including blind or image-guided, or surgical 53 
open pleural biopsy (7). Diagnosis using pleural fluid is, in reality, the norm despite several 54 
drawbacks including limited sensitivity and specificity.  55 
Xpert MTB/RIF a fully automated quantitative real-time PCR assay, until recently, the 56 
frontline test for TB in many endemic countries (8) had a poor yield in pleural TB (using 57 
pleural fluid) with a pooled sensitivity of  ~25% when using culture and pleural biopsy as a 58 
reference standard (9-11).  59 
However, more recently Cepheid developed the next-generation Xpert MTB/RIF Ultra 60 
(ULTRA) a multiplex nested PCR assay, which is WHO-endorsed as the new sputum-based 61 
frontline TB diagnostic test (12). Its key advantage is a higher sensitivity with the level of 62 
detection decreasing from ~130 to ~ 20 organisms/ ml of sample. This ~log difference in 63 
sensitivity provided hope that pauci-baciliary TB, including forms of EPTB like pleural TB, 64 
could now be more easily diagnosed (13). However, there are no comprehensive studies 65 
about the utility of ULTRA in pleural TB and none from endemic countries. A preliminary 66 
laboratory-based study detected 10 Ultra positives (sensitivity of ~47%) in selected culture 67 
positive pleural fluid samples; given that culture sensitivity is only ~40% the key drawback 68 
was one of selection and sampling bias (14). Thus, it is unknown how the performance of 69 
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ULTRA compares with the conventional Xpert MTB/RIF assay for the diagnosis of pleural 70 
TB in unselected patients. 71 
Given the drawbacks of microbiological tests and biomarkers to aid in pleural TB diagnosis, 72 
such as adenosine deaminase (ADA), have been extensively studied (7) though specificity 73 
may be limited at the 30IU/L cut-point (often used in clinical practice)  (15). An alternative 74 
biomarker, interferon gamma (IFN-γ), an inflammatory cytokine secreted by macrophages 75 
and CD4 (+) T cells becomes highly compartmentalised in TB with pooled sensitivity and 76 
specificity estimates of 93% and 96%, respectively (3) and even higher sensitivities in high 77 
TB burden settings (16, 17). The Inter-Gam Ultrasensitive Rapid Immuno-Suspension Assay 78 
(IRISA-TB) is a recently validated and standardised same-day (1.5-hour turn-around time), 79 
low-cost immunoassay assay developed to measure unstimulated IFN-γ in EPTB. Its 80 
performance relative to ULTRA has, hitherto, not been evaluated. 81 
To address these gaps in our knowledge we performed unbiased evaluation of the 4th 82 
generation Xpert cartridge (Xpert MTB/RIF), Xpert ULTRA, ADA and IRISA-TB in 83 
consecutively recruited patients in a prospective observational study using a comprehensive 84 
composite reference standard comprising culture and pleural biopsy histology.  85 
  86 
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Methods 87 
Patient recruitment, categorization and routine laboratory tests. 88 
Patients with suspected pleural TB (any TB symptoms including any cough, fever, night 89 
sweats, loss of weight, haemoptysis and/or chest pain, and features consistent with a pleural 90 
effusion on chest x-ray) were prospectively recruited from Groote Schuur Hospital in Cape 91 
Town, South Africa. The University of Cape Town Human Research Ethics Committee 92 
approved the study (HREC: 421/2006 and 919/2014). All patients provided informed consent 93 
for study participation. 94 
Pleural fluid was collected by ultrasound-guided pleurocentesis. A closed pleural biopsy, 95 
although not routine, was performed using an Abrams needle to aid in patient categorization. 96 
Biopsies were collected following aspiration of pleural fluid. Pleural fluid samples were 97 
subjected to routine biochemical and cytological analysis by the National Health Laboratory 98 
Services (NHLS). This included protein, albumin, ADA, glucose, differential cell counts, 99 
cytology, concentrated fluorescence smear microscopy, and liquid culture for M. tuberculosis 100 
using the MGIT 960 (Becton Dickinson, Sparks, Maryland). Pleural fluid ADA levels 101 
>30U/L, were reported as suggestive of pleural TB in accordance with national guidelines 102 
(18). The remaining fluid was bio-banked and frozen at -80°C and subsequently used for 103 
ULTRA, Xpert MTB/RIF and IRISA-TB analysis. Pleural biopsy samples were sent for 104 
histology and/or liquid culture. When possible, sputum was also collected for routine smear 105 
microscopy and liquid culture by the NHLS. HIV testing was performed in consenting 106 
patients. 107 
Due to the limitations of a single pleural fluid TB culture for confirming a diagnosis, a 108 
composite reference standard was used for patient categorization (and this reference standard 109 
was used in all analyses presented). Patients were categorised as follows: (i) Definite-TB: 110 
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patients with at least one positive M. tuberculosis culture (pleural fluid, biopsy and/or 111 
sputum) and/or caseating granulomatous inflammation suggestive of TB on histological 112 
examination of pleural biopsy tissue, and with improvement on anti-TB treatment (all 113 
patients in this category received anti-TB treatment); (ii) Probable-TB: patients not meeting 114 
the criteria for definite-TB but with clinical and radiological indicators suggestive of TB and 115 
who were initiated on and responded to anti-TB treatment (all patients in this category 116 
received anti-TB treatment); (iii) Non-TB: patients with  no microbiological or histological 117 
evidence of M. tuberculosis and/or an alternative diagnosis was available. These patients did 118 
not receive anti-TB treatment either at presentation or on follow-up. 119 
 120 
IFN-γ measurement 121 
Interferon-gamma concentrations were measured in pleural fluid supernatants using the 122 
IRISA-TB Assay (IRISA-TB; Antrum Biotech Pty Ltd., Cape Town, South Africa) according 123 
to the manufacturer’s instructions. The assay was performed in duplicate and the average 124 
value reported. Pleural fluid supernatant was prepared by centrifuging 1ml of pleural fluid at 125 
3000×g for 15 minutes.  126 
 127 
ULTRA and Xpert MTB/RIF assays 128 
Both the ULTRA and Xpert MTB/RIF assays were performed using 1ml of pleural fluid 129 
diluted with 2 ml of Xpert sample buffer followed by vigorous mixing. ULTRA and Xpert 130 
MTB/RIF cartridges were run on a GeneXpert 4-module machine (Cepheid, Dx System 131 
Version 4.7b). To evaluate the effect of sample concentration on ULTRA and Xpert 132 
MTB/RIF sensitivity, a median (IQR) of 10 (5-10) ml pleural fluid was centrifuged at 3000×g 133 
for 15 minutes and the corresponding pellet was resuspended in 1ml of PBS. The sample was 134 
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then processed as described for unconcentrated samples. PCR inhibition was evaluated by 135 
comparing the PCR cycle-threshold (Ct) values of the internal positive control (lyophilized 136 
Bacillus atrophaeus subsp. globigii spores) from neat and concentrated samples. The limit of 137 
detection (LOD) of ULTRA and Xpert MTB/RIF was determined in triplicate by serially 138 
diluting H37Rv CFUs (0 to 125 CFU/ml) into 1ml aliquots of non-TB pleural fluid sample. 139 
The limit of detection (LOD) of ULTRA and Xpert MTB/RIF was determined by spiking 1ml 140 
pleural fluid samples with known concentrations of H37Rv (0 to 125 CFU/ml). An H37Rv 141 
stock solution was aspirated several times using a fine gauge needle to prevent aggregation, 142 
followed by performing serial dilutions into a 0.25% Tween-80/PBS solution, as performed 143 
in previous studies (17, 19, 20). Equal volumes of each dilution were then added to 1ml of 144 
non-TB pleural fluid samples in triplicate. The CFU/ml of each dilution was confirmed by 145 
enumeration on OADC-enriched 7H10 agar.  146 
Statistical analysis 147 
Diagnostic accuracy, including 95% confidence intervals (95% CIs), was assessed using 148 
sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and 149 
area under the receiver operator curve (AUROC) in definite-TB and non-TB groups. 150 
Unpaired and paired categorical variables were compared using the χ2 and McNemar test, 151 
respectively. Continuous variables were compared using Student’s t-test where appropriate. 152 
The Mann-Whitney and Wilcoxon Rank Sum test was used for unpaired and paired non-153 
parametric continuous variables, respectively. Statistical analyses were performed using 154 
GraphPad Prism (version 6.0), Medcalc Version 18.6 and Microsoft Excel. PPV, NPV and 155 
likelihood ratios were compared by DEAD, Semiquant 156 
(https://semiquant.shinyapps.io/DEAD/).  157 
  158 
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Results 159 
Clinical and demographic data 160 
A total of 165 patients were recruited into the study; 49 subjects had definite-TB, 84 were 161 
classified as non-TB and 16 subjects were classified as probable TB. Those with non-TB 162 
effusions had a spectrum of malignant and non-malignant diagnoses including lymphoma, 163 
adenocarcinoma, small cell carcinoma, and parapneumonic effusion. An additional 16 164 
patients had insufficient clinical data to be categorized in the above groups and were 165 
subsequently excluded. A study overview is provided in Figure 1. Demographic and clinical 166 
data are summarized in Table 1.  167 
Performance outcomes of IRISA-TB 168 
The median (IQR) of the IFN-γ levels (n=149) were significantly higher in definite-TB 169 
compared to non-TB pleural effusions: [198.7pg/ml (93.4-298.2) vs. 0.0pg/ml (0.0-0.0), 170 
p<0.0001; Figure 2A]. Using Definite and Non-TB groups, a ROC curve-derived rule-in cut-171 
point of 20.5pg/ml (Figure 2B, the sensitivity (95% CI), specificity, PPV and NPV of IRISA-172 
TB was 89.8% (81.3-98.3), 96.4% (92.4-100), 93.6% (86.6-100) and 94.2% (89.2-99.1), 173 
respectively. Table 2 compares the diagnostic accuracy of IRISA-TB with other same-day 174 
diagnostics in the definite-TB versus non-TB groups.  175 
 176 
Performance outcomes of pleural fluid ADA 177 
Median (IQR) of the ADA levels (n=140) were approximately 5 times higher in definite-TB 178 
compared to non-TB effusions [55.6 (41.7-65.9) vs. 12.0 (1.0-22.4) U/L, p<0.0001]. Using a 179 
clinical cut point of  >30 U/L (18), the sensitivity (95%CI), specificity, PPV and NPV of 180 
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ADA were 84.4% (73.9-95.0), 87.5% (79.9-95.1), 80.9% (69.6- 92.1) and 90.0% (83.0-97.0), 181 
respectively (Table 2). The scatter plot and ROC of ADA are shown in Figures 2A and 2B.  182 
 183 
Performance outcome of ULTRA and Xpert MTB/RIF 184 
The sensitivity (95%CI) of ULTRA (n=149) was marginally better than Xpert MTB/RIF 185 
[37.5% (23.8-51.2) vs. 28.6% (15.9-41.2), p=0.393; Table 2]. Pleural fluid concentration did 186 
not significantly improve the sensitivity of either ULTRA or Xpert MTB/RIF, [29.5% vs. 187 
31.3% and 29.5% vs. 33.4%, respectively; Table 3]. The median (IQR) cycle-threshold 188 
values of the Xpert MTB/RIF internal positive control was significantly different between 189 
neat and concentrated samples, [26.3 vs. 25.55, p=0.0483] but not when using ULTRA 190 
(Figure S1). ULTRA had a lower LOD compared to Xpert MTB/RIF (18.7 CFU/ml vs. ≥76.2 191 
CFU/ml of pleural fluid, respectively; Figure S2). Furthermore, the lowest dilution to provide 192 
a trace positive result by ULTRA was 8.8 CFU/ml.  193 
  194 
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Discussion 195 
Given that a reliable same-day diagnostic tool for pleural TB is still lacking, we prospectively 196 
evaluated the utility of ADA, IRISA-TB, Xpert MTB/RIF and the recently released ULTRA 197 
assay for the diagnosis of pleural TB. Our key findings were that (i) ULTRA sensitivity was 198 
no better  than the conventional Xpert MTB/RIF despite a lower in vitro limit-of-detection, 199 
(ii) the ULTRA sensitivity was not improved by pelleting of larger volumes of pleural fluid, 200 
(iii) ADA and IRISA-TB had significantly higher sensitivity for pleural TB compared to 201 
molecular tests, and (iv) compared to ADA, IRISA-TB had significantly better  specificity 202 
and positive predictive value making it the ideal rule in test for pleural TB (though it also had 203 
a very high NPV in a high burden setting thus prompting clinicians when to search for 204 
alternative diagnoses that may mandate pleural biopsy and thoracoscopy). There are a 205 
number of strengths and novel aspects of our study. It is the first study to comprehensively 206 
evaluate Xpert Ultra in patients with suspected pleural TB (and directly against the Xpert G4 207 
cartridge),  it is the largest study to date (149 participants) to evaluate a nucleic acid 208 
amplification test,  ADA, and unstimulated IFN-γ in tandem, the first study to evaluate Ultra 209 
for pleural TB in the context of HIV co-infection, and evaluated an updated version of the 210 
IFN-γ assay. The use of a composite reference standard (culture and histopathology) better 211 
reflects the true performance of each assay (as culture alone is an imperfect gold standard in 212 
this context).  213 
 214 
The ULTRA cartridge, which incorporates a larger input sample volume and two different 215 
multi-copy amplification targets (IS6110 and IS1081) results in approximately 10-fold 216 
improvement in the lower limit of detection in vitro using spiked M.tb (13), yet the sensitivity 217 
in clinical samples remained suboptimal and not much different from the conventional 218 
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MTB/RIF cartridge.  This is most likely due to the immune-mediated and paucibacilliary 219 
nature of pleural TB, which remains below the detection limit (even) of ULTRA. The only 220 
published data on ULTRA in pleural TB comes from a low burden setting using samples 221 
from different extra-pulmonary sites, and that only included a small number (n=24) of pleural 222 
fluid samples (14). Furthermore, culture positivity was used as the reference standard 223 
resulting in sample and selection bias (only 40% of pleural TB is culture positive), which 224 
may have overestimated test specificity. Given that culture positivity self-selects for higher 225 
burden of microbiological disease, restricting analysis to this sub-group is also likely to 226 
overestimate sensitivity. We have also confirmed the limit of detection of the ULTRA was 227 
10-fold lower than Xpert MTB/RIF (8.8 vs. 76.2 CFU/ml, respectively). Pleural fluid is 228 
known to have inhibitory molecules which can affect molecular assays (21). However, no 229 
PCR inhibition of the positive internal control was seen when using the ULTRA assay, 230 
whereas inhibition was seen with the Xpert MTB/RIF assay (but not in a previous study that 231 
we performed, presumably due to a sample size effect) (17). Pellet-based concentration of the 232 
pleural fluid by centrifugation and resuspension did not improve sensitivity of either ULTRA 233 
or Xpert MTB/RIF. The median time to positivity was 22 days, indicating a low bacterial 234 
load within the fluid. Furthermore, ULTRA-positive culture-positive samples tended to have 235 
a shorter time to positivity than the ULTRA-negative culture-positive ones (data not shown), 236 
confirming the perception that pleural fluid is highly paucibacillary (and concentrating of 237 
10ml of pleural fluid is unlikely to improve performance despite ULTRA being more 238 
sensitive). Moreover, concentrating volumes larger than 10 ml is unlikely to improve 239 
sensitivity as centrifuging as much 100ml of fluid does not improve the diagnostic yield of 240 
culture (22), which has a similar limit of detection as ULTRA (13, 23). This is in 241 
contradistinction to TB meningitis and genitourinary/ disseminated TB in advanced HIV, 242 
where concentrating the (CSF or urine) fluid improves the sensitivity Xpert MTB/RIF (24, 243 
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25). This is likely because TB serositis is more of an immune-reactive disease characterised 244 
by a hypersensitivity reaction to TB antigens in addition to mycobacterial invasion of the 245 
pleural space. Thus, whilst we have previously shown that CSF (24) and urine centrifugation 246 
(25) may improve sensitivity, concentration in the case of a hypersensitivity reaction will 247 
have little effect given the very low burden of mycobacteria or TB antigen. The same 248 
phenomenon is likely to explain the lack of a concentration effect in TB pericarditis as we 249 
have previously shown (26).     250 
 251 
In high TB settings such as South Africa, a high ADA level (30 IU/L cut-point) is frequently 252 
used to guide initiation of anti-TB treatment. In this study, using the accepted laboratory cut-253 
point of 30 IU/L, about one fifth of the TB patients would have been missed, and close to 1 in 254 
every 10 non-TB patients would have erroneously been initiated on unnecessary anti-TB 255 
treatment. In high prevalence settings, ADA has satisfactory diagnostic performance but in 256 
lower settings the PPV is not clinically useful (27).  The most recent meta-analysis reported a 257 
sensitivity and specificity of 86% and 88%, respectively (28), confirming the 258 
misclassification bias and that 1 out of every 9 or 10 non-TB patients would be erroneously 259 
placed on anti-TB treatment (at a 10% disease prevalence this would amount to about 10 260 
additional false TB starts in every 100 patients suspected with pleural TB). The specificity of 261 
ADA can be improved if the proportion of lymphocytes are taken into account (27). 262 
However, this was not routinely requested by the attending clinician and was not expressly 263 
part of our study protocol. Furthermore, a significant proportion (~25%) of pleural effusions 264 
are neutrophil predominant (29) and lymphocyte counts in pleural fluid are not widely 265 
accessible (for the same reason it is not frequently requested in our setting). As such, this 266 
analysis was not performed. 267 
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 268 
IRISA-TB sensitivity, like that of ADA, was significantly higher than ULTRA highlighting 269 
that tests requiring to express detection of M.tb will always struggle to reach the sensitivity of 270 
immunodiagnostic tests (which can greatly reduce the need for invasive biopsy procedures). 271 
Indeed, we have confirmed our previous findings, and those of others, that IFN-γ is both a 272 
good rule-in and rule-out diagnostic test for pleural-TB (16, 17, 30-32). We used the IRISA-273 
TB kit, which is both rapid and inexpensive and can be used in most resource poor settings 274 
where other routine ELISAs are performed; moreover, it gets around the hurdle of long assay 275 
times and high cost of research-based kits, which remain un-validated in a clinical setting. 276 
The latter is important as EPTB compartments have high concentrations of interfering 277 
heterophile molecules and thus kit-based variation in sensitivity can be considerable (33-35). 278 
Interferon gamma levels were also found to be elevated in three non-TB patients. Two of 279 
these three patients showed similar histopathology and ADA levels but there was no 280 
alternative clinical diagnosis to explain the IFN-γ results with the available clinical 281 
information. One drawback of using immunodiagnostic tests is the lack of antimicrobial 282 
susceptibility data, which requires either a culture isolate or positive nucleic acid 283 
amplification test. However, the diagnostic yield in pleural fluid for both is low making this 284 
concern redundant. The diagnostic yield can be improved with pleural biopsy specimens (30). 285 
Indeed, in the current study pleural fluid culture sensitivity (45%) was lower compared to 286 
biopsy culture sensitivity (82%; data not shown). Recently, Christopher et al, showed a 30% 287 
increase in Xpert MTB/RIF sensitivity when using pleural tissue in addition to pleural fluid 288 
i.e. macerated pleural tissue was used in the Xpert assay (36). This approach was not 289 
undertaken in our study but would have still meant that ULTRA sensitivity would have been 290 
in the region of ~50%. Further studies are required to interrogate this issue though its 291 
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importance is mitigated by the fact that pleural biopsy is not routinely performed in most TB 292 
endemic settings.  293 
There are several limitations of our study. There was a low proportion of HIV-infected 294 
patients and many patients with unknown HIV status. However, the HIV prevalence rates 295 
among TB patients in the Western Cape Province are known to be lower than the rest of 296 
South Africa (37) and patients often refuse testing. Nevertheless, our findings were still 297 
derived in a TB-endemic sitting with a relatively high HIV co-infection rate where Beijing 298 
strains predominate, and thus should ideally be confirmed in other settings. A further 299 
limitation is that we did not evaluate the potential impact on morbidity and length of hospital 300 
stay of ADA, IRISA-TB, Xpert MTB/RIF and ULTRA compared to empiric treatment. 301 
However, our study design did not lend itself to deriving these measures (it would have 302 
required a RCT) and an interventional study design would have been difficult to interpret 303 
because of high rates of empiric treatment.  Lastly, as TB-IRISA was performed on frozen 304 
pleural fluid samples, it is possible that cell lysis due to freeze/thaw may have resulted in 305 
slightly inflated IFN-γ levels, when compared to freshly run samples. However, we believe 306 
this effect to be negligible based on correspondence with the manufacturer, and as IFN-γ 307 
protein is rapidly released from cells (other methods of IFN-γ detection, such as flow 308 
cytometry, require protocols that inhibit the secretion of intracellular cytokines to reliably 309 
detect them). The effect of freeze thaw on ADA is also uncertain. 310 
In conclusion, despite a better limit of detection than the conventional Xpert MTB/RIF 311 
cartridge, ULTRA has poor sensitivity for the diagnosis of pleural TB.  Biomarkers, such as 312 
ADA and IRISA-TB are significantly more sensitive, with IRISA-TB demonstrating a higher 313 
specificity and rule-in value, compared to ADA, in a TB and HIV-endemic setting.  314 
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Table 1: Baseline characteristics of the definite, probable, and non-TB groups.  432 
Continuous data analysed by unpaired t-test; categorical data analysed by Chi-squared test. 433 
Superscript symbols: a and b:  were used to indicate which groups were being compared for statistical 434 
analysis. * CD4 counts are available for all HIV infected individuals unless otherwise stated. **One 435 
definite HIV infected TB patient did not have an available CD4 count result. As such the median CD4 436 
counted is reported for 8 patients. See table S1 for number of Definite TB participants that were 437 
culture and histological positive; culture-negative and histological positive; culture positive and 438 
histological positive; culture positive with no histology requested and histology positive with culture 439 
requested.    440 
Demographic data Definite TB 
(n = 49) 
Non-TB 
(n = 84) 
Probable TB 
(n = 16) 
P-Values 
Median Age  
(IQR) 
39ᵄ 
(28 - 57) 
61ᵄᵊ 
(54 - 69) 
47ᵊ 
(38 - 53) 
ᵄ: p < 0.0001 
ᵊ: P < 0.0001 
Sex     
Male 32 (21.5%) 54 (36.2%) 10 (6.7%)  
Female 17 (11.4%) 30 (20.1%) 6 (4.0%)  
HIV-infected     
Yes 9 (6.5%) 4 (2.9%) 4 (2.9%)  
No  29 (20.9%) 45 (32.4%) 8 (5.8%)  
Unknown 5 (3.6%) 15 (10.8%) 1 (0.7%)  
Not tested 5 (3.9%) 13 (9.4%) 1 (0.7%)  
Median CD4 count* 
(cells/ml) (IQR) 
102** 
(73 - 232) 
117 
(39 - 493) 
163 
(57 - 462) 
 
Previous TB     
Yes 9 (6.0%) 9 (6.0%) 5 (3.4%)  
No 32 (21.5%) 61 (40.9%) 7 (4.7%)  
Unknown 8 (5.4%) 14 (9.4%) 4 (2.7%)  
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Table 2: Accuracy of Xpert G4, ULTRA, IRISA-TB, and ADA for the diagnosis pleural tuberculosis 441 
A positive M.tb pleural fluid, biopsy and/or sputum culture and/or histology in keeping with M.tb infection used as a reference for Definite TB. No 442 
microbiological or histological evidence of M.tb and/or an alternative diagnosis was available was defined as Non-TB. CI: confidence interval, ADA: 443 
adenosine deaminase. IRISA-TB IFN-γ cut-point of 20.5 pg/ml. ADA clinical cut point of 30 U/L is used for clinical decision-making. Superscript symbols: a; 444 
b; c; d; e; f; g; h; i; j; k; l; m; n; p; q; r; s and t:  were used to indicate which groups were being compared for statistical analysis. 445 
 Sensitivity 
% (CI) 
n/N 
Specificity 
% (CI) 
n/N 
Positive 
Predictive 
Value % (CI) 
n/N 
Negative 
Predictive 
Value % (CI) 
n/N 
Positive 
Likelihood 
Ratio  (CI) 
 
Negative 
Likelihood 
Ratio  (CI) 
 
Diagnostic odds 
Ratio 
 (CI) 
 
Xpert ULTRA 37.5bd 
(23.8 – 51.2) 
18/48 
98.8f 
(96.5 - 100) 
83/84 
94.7j 
(84.7 – 100) 
18/19 
73.5nk 
(65.3 – 81.6) 
83/113 
31.5 
(4.3 – 228.6) 
0.6qt 
(0.5 - 0.8) 
49.8 
(6.4 – 389.4) 
Xpert 
MTB/RIF  
28.6ac 
(15.9 – 41.2) 
14/49 
98.8e 
(96.4 - 100) 
83/84 
93.3i 
(80.7 - 100) 
14/15 
70.3ml 
(62.1 – 78.6) 
83/118 
24.0 
(3.2 – 177.0) 
0.7sr 
(0.6 - 0.9) 
33.2 
(4.2 – 262.3) 
IRISA-TB 
- Cut point  
20.5 pg/ml 
89.8ab 
(81.3 –  98.3)  
44/49 
96.4g 
(92.4 – 100)  
81/84 
93.6 h 
(86.6 – 100)  
44/47 
94.2kl 
(89.2 – 99.1)  
81/86 
25.1p 
(8.2 –  76.7) 
0.1qs 
(0.0 - 0.2) 
  
237.6 
(54.2 – 1041.3) 
ADA 
- Cut point 
30 IU/ml 
84.4cd 
(73.9 – 95.0)  
38/45 
87.5feg 
(79.9 – 95.1)  
63/72 
80.9 hij 
(69.6 -  92.1)  
38/47 
90.0mn 
(83.0 -  97.0)  
63/70 
6.8p 
(3.6 – 12.6) 
0.2rt 
(0.1 - 0.4) 
38.0 
(13.1 – 110.4) 
P-value a; b; c and d:   
p < 0.0001 
e: p=0.004 
 f: p=0.005 
g: p = 0.034 
 
h: p = 0.028 
i: p = 0.071 
j: p = 0.032 
k; l  and m:  
p < 0.0001 
n: p = 0.00013 
 
p: p = 0.032 q; r  and s:  
p < 0.0001 
t: p = 0.0006 
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Table 3: Sensitivity and specificity of ULTRA and Xpert MTB/RIF assay using unprocessed 446 
and concentrated (pellet centrifugation) pleural fluid to diagnose pleural tuberculosis 447 
Two aliquots of a median volume of 10 ml of pleural fluid was centrifuged at 3000 × g for 15 min 448 
with the pellet resuspended in sterile PBS, followed by Xpert MTB/RIF and ULTRA. A positive M.tb 449 
pleural fluid, biopsy and/or sputum culture and/or histology in keeping with M.tb infection used as a 450 
reference for Definite TB. No microbiological or histological evidence of M.tb and/or an alternative 451 
diagnosis was available was defined as Non-TB. CI: confidence interval. a: Error (n=1) in the 452 
concentrated ULTRA. b: Error (n=2) in the concentrated Xpert MTB/RIF. 453 
  454 
 ULTRA Xpert MTB/RIF 
 Sensitivity 
% (CI) 
n/N 
Specificity 
% (CI) 
n/N 
Sensitivity 
% (CI) 
n/N 
Specificity 
% (CI) 
n/N 
Fluid  29.5 
(13.3 - 53.2) 
5/17 
100 
(89.6 - 100) 
34/34 
29.5 
(13.3 - 53.2)  
5/17 
100 
(89.9 - 100)  
34/34 
Concentrated 31.3 
(14.2 -  55.6) 
5/16a 
100 
(89.6 - 100) 
33/33 
33.4 
(15.2 -  58.3)  
5/15b 
100 
(89.3 - 100)  
32/32 
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Figure Legends: 455 
Figure 1. Study overview of patient groups, investigations performed, and tests 456 
undertaken. 457 
a No biopsy taken, n=10; b Fluid smear not requested, n=40; c Sputum smear not requested, 458 
n=1; d Histology not requested, n=11; e Fluid culture not requested, n=25; f Sputum culture not 459 
requested, n=3; g Biopsy culture not requested, n=66; h ADA levels not requested, n=25; I 460 
Contamination, n=1; j Biopsy sample sub-optimal for histology, n=13; k Errors, n=2. m 461 
Insufficient clinical data for final diagnosis. Participants classifications: Definite-TB: at least 462 
one positive M. tb culture (pleural fluid, biopsy and/or sputum) and/or caseating 463 
granulomatous inflammation suggestive of TB on histological examination of pleural biopsy 464 
tissue, and with improvement on anti-TB treatment; Probable-TB: patients not meeting the 465 
criteria for definite-TB but with clinical and radiological indicators suggestive of TB and who 466 
were initiated on and responded to anti-TB treatment, Non-TB: patients with  no 467 
microbiological or histological evidence of M. tb and/or an alternative diagnosis was 468 
available.  469  o
n
 July 19, 2019 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
26 
 
 470 
Figure 2: A) Scatter plot of IFN-γ levels using IRISA-TB and adenosine deaminase ADA) using pleural fluid from patients with Definite TB and 471 
Non-TB pleural effusions. *Mann-Whitney. ROC derived cut point of 20.5 pg/ml IFN-γ (indicated by          ) for IRISA-TB and ADA cut point of 30 IU/l 472 
(indicated by            ). B): Area under the receiver operator characteristic (ROC) curves for IRISA-TB and adenosine deaminase (ADA). Area under 473 
the curve; IRISA-TB: 0.94 and ADA: 0.88, respectively. The ROC curves where generated using the Definite and Non-TB groups with the chosen cut point 474 
for IRISA-TB indicated with an arrow. No significant difference was observed between the two ROC curves when using the Hanley & McNeil method. 475 
 476 
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